ELSEVIER

Diabetes Research and Clinical Practice 56 (2002) 229–231

DIABETES RESEARCH
AND
CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 56

Abdul-Rasoul, M., H. Al-Qattan, A. Al-Haj, H. Habib, A. Ismael, Incidence and seasonal variation of Type 1 diabetes in children in Farwania area, Kuwait (1995–1999) **56**, 153
Adachi, Y., see Furuta, M. **56**, 141
Adachi, Y., see Furuta, M. **56**, 159
Adjei, S., see Amoah, A.G.B. **56**, 197
Aguilar, M., see Carral, F. **56**, 27
Aguilar, M., see Soriguer-Escofet, F. **56**, 213
Albert, S.G., see DeLeon, M.J. **56**, 101
Al-Haj, A., see Abdul-Rasoul, M. **56**, 153
Al-Qattan, H., see Abdul-Rasoul, M. **56**, 153
Amoah, A.G.B., S.K. Owusu, S. Adjei, Diabetes in Ghana: a community based prevalence study in Greater Accra **56**, 197
Apelqvist, J., see Hjelm, K. **56**, 49
Araki, E., see Toyonaga, T. **56**, 13
Araki-Sasaki, R., see Furuta, M. **56**, 141
Araki-Sasaki, R., see Furuta, M. **56**, 159

Banchuin, N., W. Boonyasrisawat, Lymphoproliferative response to glutamic acid decarboxylase in fibrocalculous pancreatopathy **56**, 77
Baranyi, É., see Winkler, G. **56**, 93
Bekris, L., see Maioli, M. **56**, 41
Boonyasrisawat, W., see Banchuin, N. **56**, 77
Buğra, Z., see Satman, I. **56**, 189

Careddu, A., see Lo Giudice, P. **56**, 173
Carminati, P., see Lo Giudice, P. **56**, 173
Carral, F., G. Olveira, J. Salas, L. García, Á. Sillero, M. Aguilar, Care resource utilization and direct costs incurred by people with diabetes in a Spanish hospital **56**, 27
Catalá, M., see Soriguer-Escofet, F. **56**, 213
Cerasi, E., Insulin responses to sulfonylureas **56**, 69
Chandurkar, V., see DeLeon, M.J. **56**, 101
Chaudhary, D., see Misra, A. **56**, 73
Choo, S.W., see Yang, T.-Y. **56**, 107
Chua, E., see Liu, D.P. **56**, 125
Chung, J.H., see Yang, T.-Y. **56**, 107
Ciccarese, M., see Maioli, M. **56**, 41
Cirillo, R., see Maioli, M. **56**, 41
Cossu, E., see Maioli, M. **56**, 41
Császár, A., see Kalina, Á. **56**, 63
Cseh, K., see Winkler, G. **56**, 93
Cuesta-Muñoz, A.L., see Soriguer-Escofet, F. **56**, 213

Daimon, M., T. Oizumi, T. Saitoh, W. Kameda, H. Yamaguchi, H. Ohnuma, M. Igarashi, H. Manaka, T. Kato, Calpain 10 gene polymorphisms are related, not to type 2 diabetes, but to increased serum cholesterol in Japanese **56**, 147
DeLeon, M.J., V. Chandurkar, S.G. Albert, A.D. Mooradian, Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects **56**, 101
Devrim, S., see Satman, I. **56**, 189
Dinççağ, N., see Satman, I. **56**, 189
Do, Y.S., see Yang, T.-Y. **56**, 107

Esteva, I., see Soriguer-Escofet, F. **56**, 213

Freire, J.M., see Soriguer-Escofet, F. **56**, 213
Fujita, H., see Kawai, T. **56**, 83
Furuta, M., Y. Yano, E.C. Gabazza, R. Araki-Sasaki, T. Tanaka, A. Katsuki, Y. Hori, K. Nakatani, Y. Sumida, Y. Adachi, Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus **56**, 159
Furuta, M., Y. Yano, K. Ito, E.C. Gabazza, A. Katsuki, T. Tanaka, K. Ohtake, N. Hirata, Y. Hori, R. Araki-Sasaki, Y. Sumida, Y. Adachi, Relationship of the tumor necrosis factor-α -308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus **56**, 141

Gabazza, E.C., see Furuta, M. **56**, 141
Gabazza, E.C., see Furuta, M. **56**, 159
García, L., see Carral, F. **56**, 27

PII: S0168-8227(02)00047-5

García-Almeida, J.M., see Soriguer-Escofet, F. **56**, 213
Gómez-Zumaquero, J.M., see Soriguer-Escofet, F. **56**, 213
Goodman, C., see Maiorana, A. **56**, 115
Green, D., see Maiorana, A. **56**, 115
Gulliford, M.C., D. Mahabir, Diabetic foot disease and foot care in a Caribbean community **56**, 35
Gürsoy, N., see Satman, I. **56**, 189

Habib, H., see Abdul-Rasoul, M. **56**, 153
Hajós, P., see Winkler, G. **56**, 93
Heine, R.J., Reply to the Letter to the Editor from van der Wal and Heine (Insulin responses to sulfonylureas) **56**, 71
Hirata, N., see Furuta, M. **56**, 141
Hirayama, Y., see Nagashima, T. **56**, 19
Hirose, H., see Kawai, T. **56**, 83
Hjelm, K., P. Nyberg, J. Apelqvist, Determinants of ambulatory care in a defined adult Swedish diabetic population **56**, 49
Hori, Y., see Furuta, M. **56**, 141
Hori, Y., see Furuta, M. **56**, 159
Hu, L.N., see Liu, D.P. **56**, 125

Igarashi, M., see Daimon, M. **56**, 147
Ishigaki, Y., see Nagashima, T. **56**, 19
Ismael, A., see Abdul-Rasoul, M. **56**, 153
Ito, K., see Furuta, M. **56**, 141
Itoh, Y., see Miyashita, Y. **56**, 181

Jensen, T., L. Musaeus, B. Molsing, B. Lyholm, T. Mandrup-Poulsen, Process measures and outcome research as tools for future improvement of diabetes treatment quality **56**, 207
Jeong, I.-K., see Yang, T.-Y. **56**, 107
Jing, H., see Liu, D.P. **56**, 125

Kalina, Á., C. Szalai, Z. Prohászka, I. Reiber, A. Császár, Association of plasma lipid levels with apolipoprotein E polymorphism in Type 2 diabetes **56**, 63
Kameda, W., see Daimon, M. **56**, 147
Karadeniz, Ş., see Satman, I. **56**, 189
Karádi, I., see Winkler, G. **56**, 93
Karşıdağ, K., see Satman, I. **56**, 189
Kato, T., see Daimon, M. **56**, 147
Katsuki, A., see Furuta, M. **56**, 141
Katsuki, A., see Furuta, M. **56**, 159
Kawai, T., H. Hirose, Y. Seto, H. Fujita, H. Fujita, K. Ukeda, T. Saruta, Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma **56**, 83
Khalid, B.A.K., see Nawawi, H.M. **56**, 221
Kian, Y.C., see Nawawi, H.M. **56**, 221
Kim, K.-W., see Yang, T.-Y. **56**, 107
Kim, S.-J., see Yang, T.-Y. **56**, 107
Kinugawa, N., see Sato, T. **56**, 133
Kodama, S., see Toyonaga, T. **56**, 13
Kondo, T., see Toyonaga, T. **56**, 13
Kovács, M., see Winkler, G. **56**, 93
Kumar, A., see Sen, K. **56**, 1

Lee, M.-K., see Yang, T.-Y. **56**, 107
Lee, M.-S., see Yang, T.-Y. **56**, 107
Lernmark, Å., see Maioli, M. **56**, 41
Liu, D.P., L. Molyneaux, E. Chua, Y.Z. Wang, C.R. Wu, H. Jing, L.N. Hu, Y.J. Liu, Z.R. Xu, D.K. Yue, Retinopathy in a Chinese population with type 2 diabetes: factors affecting the presence of this complication at diagnosis of diabetes **56**, 125
Liu, Y.J., see Liu, D.P. **56**, 125
Lo Giudice, P., A. Careddu, G. Magni, T. Quagliata, L. Pacifici, P. Carminati, Autonomic neuropathy in streptozotocin diabetic rats: effect of acetyl-L-carnitine **56**, 173
Lyholm, B., see Jensen, T. **56**, 207

Magni, G., see Lo Giudice, P. **56**, 173
Mahabir, D., see Gulliford, M.C. **56**, 35
Maioli, M., G. Tonolo, L. Bekris, R. Cirillo, D. Schranz, E. Cossu, M. Ciccarese, Å. Lernmark, GAD65 and IA-2 autoantibodies are common in a subset of siblings of Sardinian Type 2 diabetes families **56**, 41
Maiorana, A., G. O'Driscoll, C. Goodman, R. Taylor, D. Green, Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes **56**, 115
Manaka, H., see Daimon, M. **56**, 147
Mandrup-Poulsen, T., see Jensen, T. **56**, 207
Melczer, Z., see Winkler, G. **56**, 93
Merelo, M.J., see Soriguer-Escofet, F. **56**, 213
Min, Y.-K., see Yang, T.-Y. **56**, 107
Misra, A., see Sen, K. **56**, 1
Misra, A., D. Chaudhary, N.K. Vikram, V. Mittal, J. Rama Devi, Insulin resistance and clustering of atherogenic risk factors in women belonging to low socio-economic strata in urban slums of North India **56**, 73
Mittal, V., see Misra, A. **56**, 73
Miyamura, N., see Toyonaga, T. **56**, 13
Miyashita, Y., K. Shirai, Y. Itoh, H. Sasaki, M. Totsuka, T. Murano, H. Watanabe, Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy **56**, 181
Miyazawa, T., see Nagashima, T. **56**, 19
Mohamud, W.N.W., see Nawawi, H.M. **56**, 221
Molsing, B., see Jensen, T. **56**, 207
Molyneaux, L., see Liu, D.P. **56**, 125
Mooradian, A.D., see DeLeon, M.J. **56**, 101
Morimoto, N., see Sato, T. **56**, 133
Muhajir, M., see Nawawi, H.M. **56**, 221
Murano, T., see Miyashita, Y. **56**, 181
Musaeus, L., see Jensen, T. **56**, 207

Nagashima, T., S. Oikawa, Y. Hirayama, Y. Tokita, A. Sekikawa, Y. Ishigaki, R. Yamada, T. Miyazawa, Increase of serum phosphatidylcholine hydroperoxide dependent on glycemic control in type 2 diabetic patients **56**, 19
Nakakado, F., see Sato, T. **56**, 133
Nakamura, Y., see Sato, T. **56**, 133
Nakatani, K., see Furuta, M. **56**, 159

Nawawi, H.M., M. Muhajir, Y.C. Kian, W.N.W. Mohamud, K. Yusoff, B.A.K. Khalid, Type of diabetes and waist–hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients **56**, 221
Nyberg, P., see Hjelm, K. **56**, 49

O'Driscoll, G., see Maiorana, A. **56**, 115
Oh, E.Y., see Yang, T.-Y. **56**, 107
Oh, S.H., see Yang, T.-Y. **56**, 107
Ohnuma, H., see Daimon, M. **56**, 147
Ohtake, K., see Furuta, M. **56**, 141
Oikawa, S., see Nagashima, T. **56**, 19
Oizumi, T., see Daimon, M. **56**, 147
Ökten, A., see Satman, I. **56**, 189
Olveira, G., see Carral, F. **56**, 27
Ortego, J., see Soriguer-Escofet, F. **56**, 213
Ovalı, T., see Satman, I. **56**, 189
Owusu, S.K., see Amoah, A.G.B. **56**, 197

Pacifici, L., see Lo Giudice, P. **56**, 173
Pandey, R.M., see Sen, K. **56**, 1
Prohászka, Z., see Kalina, Á. **56**, 63

Quagliata, T., see Lo Giudice, P. **56**, 173

Rama Devi, J., see Misra, A. **56**, 73
Reiber, I., see Kalina, Á. **56**, 63
Rojo-Martinez, G., see Soriguer-Escofet, F. **56**, 213
Ruiz de Adana, S., see Soriguer-Escofet, F. **56**, 213

Saitoh, T., see Daimon, M. **56**, 147
Salamon, F., see Winkler, G. **56**, 93
Salas, J., see Carral, F. **56**, 27
Saruta, T., see Kawai, T. **56**, 83
Sasaki, H., see Miyashita, Y. **56**, 181
Satman, I., M.T. Yılmaz, N. Gürsoy, K. Karşıdağ, N. Dinççağ, T. Ovalı, Ş. Karadeniz, V. Uysal, Z. Buğra, A. Ökten, S. Devrim, Evaluation of insulin resistant diabetes mellitus in Alström syndrome: a long-term prospective follow-up of three siblings **56**, 189
Sato, T., N. Morimoto, N. Tsutsu, F. Nakakado, N. Kinugawa, Y. Nakamura, Background factors correlated with the psychological features of 254 outpatients with Type 2 diabetes mellitus in Japan **56**, 133
Schranz, D., see Maioli, M. **56**, 41
Sekigami, T., see Toyonaga, T. **56**, 13
Sekikawa, A., see Nagashima, T. **56**, 19
Sen, K., A. Misra, A. Kumar, R.M. Pandey, Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia **56**, 1
Seo, I.A., see Yang, T.-Y. **56**, 107
Seto, Y., see Kawai, T. **56**, 83
Shirai, K., see Miyashita, Y. **56**, 181
Shirakami, A., see Toyonaga, T. **56**, 13
Shirotani, T., see Toyonaga, T. **56**, 13
Sillero, Á., see Carral, F. **56**, 27
Sonoda, K., see Toyonaga, T. **56**, 13
Soriguer-Escofet, F., I. Esteva, G. Rojo-Martinez, S. Ruiz de Adana, M. Catalá, M.J. Merelo, M. Aguilar, F. Tinahones, J.M. García-Almeida, J.M. Gómez-Zumaquero, A.L. Cuesta-Muñoz, J. Ortego, J.M. Freire, Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain **56**, 213
Speer, G., see Winkler, G. **56**, 93
Sumida, Y., see Furuta, M. **56**, 141
Sumida, Y., see Furuta, M. **56**, 159
Szalai, C., see Kalina, Á. **56**, 63

Tanaka, T., see Furuta, M. **56**, 141
Tanaka, T., see Furuta, M. **56**, 159
Taylor, R., see Maiorana, A. **56**, 115
Tinahones, F., see Soriguer-Escofet, F. **56**, 213
Tokita, Y., see Nagashima, T. **56**, 19
Tonolo, G., see Maioli, M. **56**, 41
Totsuka, M., see Miyashita, Y. **56**, 181
Toyonaga, T., T. Kondo, N. Miyamura, T. Sekigami, K. Sonoda, S. Kodama, A. Shirakami, T. Shirotani, E. Araki, Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus **56**, 13
Tsutsu, N., see Sato, T. **56**, 133
Turi, Z., see Winkler, G. **56**, 93

Ukeda, K., see Kawai, T. **56**, 83
Uysal, V., see Satman, I. **56**, 189

Vargha, P., see Winkler, G. **56**, 93
Vikram, N.K., see Misra, A. **56**, 73

Wang, Y.Z., see Liu, D.P. **56**, 125
Watanabe, H., see Miyashita, Y. **56**, 181
Winkler, G., K. Cseh, É. Baranyi, Z. Melczer, G. Speer, P. Hajós, F. Salamon, Z. Turi, M. Kovács, P. Vargha, I. Karádi, Tumor necrosis factor system in insulin resistance in gestational diabetes **56**, 93
Wu, C.R., see Liu, D.P. **56**, 125

Xu, Z.R., see Liu, D.P. **56**, 125

Yamada, R., see Nagashima, T. **56**, 19
Yamaguchi, H., see Daimon, M. **56**, 147
Yang, T.-Y., S.H. Oh, I.-K. Jeong, I.A. Seo, E.Y. Oh, S.-J. Kim, J.H. Chung, Y.-K. Min, M.-S. Lee, M.-K. Lee, K.-W. Kim, Y.S. Do, S.W. Choo, First human trial of pancreatic islet allo-transplantation in Korea—focus on re-transplantation **56**, 107
Yano, Y., see Furuta, M. **56**, 141
Yano, Y., see Furuta, M. **56**, 159
Yılmaz, M.T., see Satman, I. **56**, 189
Yue, D.K., see Liu, D.P. **56**, 125
Yusoff, K., see Nawawi, H.M. **56**, 221

ELSEVIER

Diabetes Research and Clinical Practice 56 (2002) 233–236

DIABETES RESEARCH
AND
CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 56

Abdominal fat distribution; Type 2 diabetes; TNF-α polymorphism; Insulin resistance; Japanese **56**, 141

Acarbose; Type 2 diabetes; Alpha-glucosidase inhibitors; Aging; Glucagon-like peptide-1 **56**, 101

Age at onset; Type 1 diabetes mellitus; Epidemiology; Incidence; Seasonality **56**, 153

Aging; Type 2 diabetes; Alpha-glucosidase inhibitors; Acarbose; Glucagon-like peptide-1 **56**, 101

Allele; Apolipoprotein E; Cholesterol; Triglyceride **56**, 63

Alpha-glucosidase inhibitors; Type 2 diabetes; Acarbose; Aging; Glucagon-like peptide-1 **56**, 101

Alström syndrome; Insulin resistance; Diabetes; Obesity; Nephro-uropathy **56**, 189

Anthropometry; Exercise training; Diabetes; Peak oxygen uptake; Maximal voluntary contraction; Glycated hemoglobin **56**, 115

Anxiety; Type 2 diabetes mellitus; Psychological; Depression **56**, 133

Apolipoprotein E; Allele; Cholesterol; Triglyceride **56**, 63

Association; Calpain-l0; Polymorphism; Cholesterol; Diabetes **56**, 147

ATP-sensitive K$^+$ channel; Troglitazone; PPAR gamma; Lipotoxicity; INS-1 cell **56**, 83

Autonomic nervous system; Diabetes; Heart rate variability; Lipid metabolism **56**, 173

Calpain-l0; Polymorphism; Association; Cholesterol; Diabetes **56**, 147

Care-seeking behaviour; Use of health care; Diabetes mellitus; Population-based study **56**, 49

Chemiluminescence-high performance liquid chromatography; Diabetes mellitus; HbA_{1c}; Phosphatidylcholine hydroperoxide **56**, 19

Chinese; Retinopathy; Complications; Screening; Diabetes **56**, 125

Cholesterol; Allele; Apolipoprotein E; Triglyceride **56**, 63

Cholesterol; Calpain-l0; Polymorphism; Association; Diabetes **56**, 147

Complications; Retinopathy; Chinese; Screening; Diabetes **56**, 125

Cost; Diabetes mellitus; Readmissions; Mortality **56**, 27

Depression; Type 2 diabetes mellitus; Psychological; Anxiety **56**, 133

Diabetes; Autonomic nervous system; Heart rate variability; Lipid metabolism **56**, 173

Diabetes; Calpain-l0; Polymorphism; Association; Cholesterol **56**, 147

Diabetes; Exercise training; Peak oxygen uptake; Maximal voluntary contraction; Anthropometry; Glycated hemoglobin **56**, 115

Diabetes; Insulin resistance; Obesity; Nephro-uropathy; Alström syndrome **56**, 189

Diabetes; Lipoprotein (a); Waist–hip ratio **56**, 221

Diabetes; Retinopathy; Complications; Chinese; Screening **56**, 125

PII: S0168-8227(02)00048-7

Diabetes mellitus; Cost; Readmissions; Mortality **56**, 27

Diabetes mellitus; Diabetic neuropathies; Diabetic foot; Foot ulceration; West Indies; Trinidad and Tobago **56**, 35

Diabetes mellitus; Diabetic retinopathy; Visual acuity; Simvastatin; Hypercholesterolemia; Triglycerides; Macular edema **56**, 1

Diabetes mellitus; HbA_{1c}; Phosphatidylcholine hydroperoxide; Chemiluminescence-high performance liquid chromatography **56**, 19

Diabetes mellitus; Islet autoantibodies; LADA; Prevalence **56**, 213

Diabetes mellitus; Islet transplantation; Islet re-transplantation **56**, 107

Diabetes mellitus; Troglitazone; GLUT4 expression; OLETF rat; Translocation **56**, 159

Diabetes mellitus; Use of health care; Care-seeking behaviour; Population-based study **56**, 49

Diabetic foot; Diabetes mellitus; Diabetic neuropathies; Foot ulceration; West Indies; Trinidad and Tobago **56**, 35

Diabetic ketoacidosis; Tacrolimus; Post-transplant diabetes mellitus **56**, 13

Diabetic neuropathies; Diabetes mellitus; Diabetic foot; Foot ulceration; West Indies; Trinidad and Tobago **56**, 35

Diabetic retinopathy; Diabetes mellitus; Visual acuity; Simvastatin; Hypercholesterolemia; Triglycerides; Macular edema **56**, 1

Epidemiology; Type 1 diabetes mellitus; Incidence; Seasonality; Age at onset **56**, 153

Exercise training; Diabetes; Peak oxygen uptake; Maximal voluntary contraction; Anthropometry; Glycated hemoglobin **56**, 115

Foot ulceration; Diabetes mellitus; Diabetic neuropathies; Diabetic foot; West Indies; Trinidad and Tobago **56**, 35

Gestational diabetes; Tumor necrosis factor (TNF)-α; Soluble TNF-receptors; Insulin resistance; Physiological pregnancy **56**, 93

Ghana; Type 2 diabetes; Prevalence; Impaired fasting glycaemia; Impaired glucose tolerance **56**, 197

Glucagon-like peptide-1; Type 2 diabetes; Alpha-glucosidase inhibitors; Acarbose; Aging **56**, 101

GLUT4 expression; Troglitazone; OLETF rat; Translocation; Diabetes mellitus **56**, 159

Glycated hemoglobin; Exercise training; Diabetes; Peak oxygen uptake; Maximal voluntary contraction; Anthropometry **56**, 115

HbA_{1c}; Diabetes mellitus; Phosphatidylcholine hydroperoxide; Chemiluminescence-high performance liquid chromatography **56**, 19

HbA_{1c}; Outcome data; Quality of care; Type 1 diabetes mellitus; Urinary albumin excretion **56**, 207

Heart rate variability; Diabetes; Autonomic nervous system; Lipid metabolism **56**, 173

Hypercholesterolemia; Diabetes mellitus; Diabetic retinopathy; Visual acuity; Simvastatin; Triglycerides; Macular edema **56**, 1

Impaired fasting glycaemia; Type 2 diabetes; Prevalence; Impaired glucose tolerance; Ghana **56**, 197

Impaired glucose tolerance; Type 2 diabetes; Prevalence; Impaired fasting glycaemia; Ghana **56**, 197

Incidence; Type 1 diabetes mellitus; Epidemiology; Seasonality; Age at onset **56**, 153

INS-1 cell; Troglitazone; PPAR gamma; Lipotoxicity; ATP-sensitive K^+ channel **56**, 83

Insulin resistance; Diabetes; Obesity; Nephro-uropathy; Alström syndrome **56**, 189

Insulin resistance; Tumor necrosis factor (TNF)-α; Soluble TNF-receptors; Gestational diabetes; Physiological pregnancy **56**, 93

Insulin resistance; Type 2 diabetes; TNF-α polymorphism; Abdominal fat distribution; Japanese **56**, 141

Insulin therapy; Preheparin LPL mass; Type 2 diabetes mellitus **56**, 181

Islet autoantibodies; Diabetes mellitus; LADA; Prevalence **56**, 213

Islet cell autoantibodies; Type 2 diabetes; LADA; Sardinia **56**, 41

Islet re-transplantation; Islet transplantation; Diabetes mellitus **56**, 107

Islet transplantation; Islet re-transplantation; Diabetes mellitus **56**, 107

Japanese; Type 2 diabetes; TNF-α polymorphism; Insulin resistance; Abdominal fat distribution **56**, 141

LADA; Diabetes mellitus; Islet autoantibodies; Prevalence **56**, 213

LADA; Type 2 diabetes; Islet cell autoantibodies; Sardinia **56**, 41

Lipid metabolism; Diabetes; Autonomic nervous system; Heart rate variability **56**, 173

Lipoprotein (a); Diabetes; Waist–hip ratio **56**, 221

Lipotoxicity; Troglitazone; PPAR gamma; INS-1 cell; ATP-sensitive K^+ channel **56**, 83

Macular edema; Diabetes mellitus; Diabetic retinopathy; Visual acuity; Simvastatin; Hypercholesterolemia; Triglycerides **56**, 1

Maximal voluntary contraction; Exercise training; Diabetes; Peak oxygen uptake; Anthropometry; Glycated hemoglobin **56**, 115

Mortality; Diabetes mellitus; Cost; Readmissions **56**, 27

Nephro-uropathy; Insulin resistance; Diabetes; Obesity; Alström syndrome **56**, 189

Obesity; Insulin resistance; Diabetes; Nephro-uropathy; Alström syndrome **56**, 189

OLETF rat; Troglitazone; GLUT4 expression; Translocation; Diabetes mellitus **56**, 159

Outcome data; Quality of care; Type 1 diabetes mellitus; HbA_{1c}; Urinary albumin excretion **56**, 207

Peak oxygen uptake; Exercise training; Diabetes; Maximal voluntary contraction; Anthropometry; Glycated hemoglobin **56**, 115

Phosphatidylcholine hydroperoxide; Diabetes mellitus; HbA_{1c}; Chemiluminescence-high performance liquid chromatography **56**, 19

Physiological pregnancy; Tumor necrosis factor (TNF)-α; Soluble TNF-receptors; Insulin resistance; Gestational diabetes **56**, 93

Polymorphism; Calpain-l0; Association; Cholesterol; Diabetes **56**, 147

Population-based study; Use of health care; Care-seeking behaviour; Diabetes mellitus **56**, 49

Post-transplant diabetes mellitus; Tacrolimus; Diabetic ketoacidosis **56**, 13

PPAR gamma; Troglitazone; Lipotoxicity; INS-1 cell; ATP-sensitive K^+ channel **56**, 83

Preheparin LPL mass; Type 2 diabetes mellitus; Insulin therapy **56**, 181

Prevalence; Diabetes mellitus; Islet autoantibodies; LADA **56**, 213

Prevalence; Type 2 diabetes; Impaired fasting glycaemia; Impaired glucose tolerance; Ghana **56**, 197

Psychological; Type 2 diabetes mellitus; Anxiety; Depression **56**, 133

Quality of care; Outcome data; Type 1 diabetes mellitus; HbA_{1c}; Urinary albumin excretion **56**, 207

Readmissions; Diabetes mellitus; Cost; Mortality **56**, 27

Retinopathy; Complications; Chinese; Screening; Diabetes **56**, 125

Sardinia; Type 2 diabetes; Islet cell autoantibodies; LADA **56**, 41

Screening; Retinopathy; Complications; Chinese; Diabetes **56**, 125

Seasonality; Type 1 diabetes mellitus; Epidemiology; Incidence; Age at onset **56**, 153

Simvastatin; Diabetes mellitus; Diabetic retinopathy; Visual acuity; Hypercholesterolemia; Triglycerides; Macular edema **56**, 1

Soluble TNF-receptors; Tumor necrosis factor (TNF)-α; Insulin resistance; Gestational diabetes; Physiological pregnancy **56**, 93

Tacrolimus; Diabetic ketoacidosis; Post-transplant diabetes mellitus **56**, 13

TNF-α polymorphism; Type 2 diabetes; Insulin resistance; Abdominal fat distribution; Japanese **56**, 141

Translocation; Troglitazone; GLUT4 expression; OLETF rat; Diabetes mellitus **56**, 159

Triglyceride; Allele; Apolipoprotein E; Cholesterol **56**, 63

Triglycerides; Diabetes mellitus; Diabetic retinopathy; Visual acuity; Simvastatin; Hypercholesterolemia; Macular edema **56**, 1

Trinidad and Tobago; Diabetes mellitus; Diabetic neuropathies; Diabetic foot; Foot ulceration; West Indies **56**, 35

Troglitazone; GLUT4 expression; OLETF rat; Translocation; Diabetes mellitus **56**, 159

Troglitazone; PPAR gamma; Lipotoxicity; INS-1 cell; ATP-sensitive K^+ channel **56**, 83

Tumor necrosis factor (TNF)-α; Soluble TNF-receptors; Insulin resistance; Gestational diabetes; Physiological pregnancy **56**, 93

Type 2 diabetes; Alpha-glucosidase inhibitors; Acarbose; Aging; Glucagon-like peptide-1 **56**, 101

Type 2 diabetes; Islet cell autoantibodies; LADA; Sardinia **56**, 41

Type 2 diabetes; Prevalence; Impaired fasting glycaemia; Impaired glucose tolerance; Ghana **56**, 197

Type 2 diabetes; TNF-α polymorphism; Insulin resistance; Abdominal fat distribution; Japanese **56**, 141

Type 1 diabetes mellitus; Epidemiology; Incidence; Seasonality; Age at onset **56**, 153

Type 1 diabetes mellitus; Outcome data; Quality of care; HbA_{1c}; Urinary albumin excretion **56**, 207

Type 2 diabetes mellitus; Preheparin LPL mass; Insulin therapy **56**, 181

Type 2 diabetes mellitus; Psychological; Anxiety; Depression **56**, 133

Urinary albumin excretion; Outcome data; Quality of care; Type 1 diabetes mellitus; HbA_{1c} **56**, 207

Use of health care; Care-seeking behaviour; Diabetes mellitus; Population-based study **56**, 49

Visual acuity; Diabetes mellitus; Diabetic retinopathy; Simvastatin; Hypercholesterolemia; Triglycerides; Macular edema **56**, 1

Waist–hip ratio; Lipoprotein (a); Diabetes **56**, 221

West Indies; Diabetes mellitus; Diabetic neuropathies; Diabetic foot; Foot ulceration; Trinidad and Tobago **56**, 35